

CORRECTION

Open Access



Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease

Craig W. Ritchie^{1,2*}, Tom C. Russ^{1,2,3,4†}, Sube Banerjee⁵, Bob Barber⁶, Andrew Boaden⁷, Nick C. Fox⁸, Clive Holmes⁹, Jeremy D. Isaacs¹⁰, Ira Leroi¹¹, Simon Lovestone¹², Matt Norton¹³, John O'Brien¹⁴, Jim Pearson¹⁵, Richard Perry¹⁶, James Pickett⁷, Adam D. Waldman¹⁸, Wai Lup Wong¹⁷, Martin N. Rossor^{8†} and Alistair Burns^{11†}

Correction

Since the publication of our article [1], it has come to our attention that we failed to include information for two of the authors in the competing interests section. Craig Richie has declared potential competing interests with the following companies; Janssen, Eisai, Pfizer, Eli Lilly, Roche Diagnostics, Boeringher Ingleheim, Novartis, AC Immune, Ixico, Aridhia, Amgen, Berry Consultants, Lundbeck, Sanofi, Quintiles (IQVIA) and Takeda. Jeremy Issacs has declared potential competing interests with the following companies; Roche and Merck & Co. The full competing interests section for this article can be found below.

Declarations

Competing interests

Bob Barber has participated in an advisory panel for Novartis on one occasion and conducted a number of pharmaceutical sponsored commercial clinical trials in Alzheimer's disease (including Lilly, Roche and Janssen). He has a national role for NIHR NHS relating to commercial studies in dementia. Nick Fox has received research support from AVID/Lilly and has advised GSK, Lilly, Novartis and Roche; he serves on a data monitoring committee for Biogen—all payments for these activities are to UCL. Clive Holmes has attended advisory boards for Lilly pharmaceuticals. Martin Rossor serves on a safety monitoring committee for Servier and has advised Merck on patient registries. Tom Russ works within NHS Scotland with the Scottish Neuroprogressive

and Dementia Network on commercial studies in dementia. Craig Richie is the co-coordinator and academic lead for the EPAD (European Prevention of Alzheimer's Dementia) Project which has numerous commercial partners in keeping with the mechanisms of the European Union's Innovative Medicine's Initiative. These companies are: Janssen, Eisai, Pfizer, Eli Lilly, Roche Diagnostics, Boeringher Ingleheim, Novartis, AC Immune, Ixico, Aridhia, Amgen, Berry Consultants, Lundbeck, Sanofi, Quintiles (IQVIA) and Takeda. Jeremy Issacs is a Principal Investigator on clinical trials, outside of the submitted work, sponsored by both Roche and Merck & Co, who supply funding to his employing organisation to conduct the study. The remaining co-authors declare that they have no competing interests. All authors have completed the ICJME declaration of conflicts of interest.

Author details

¹Centre for Dementia Prevention, University of Edinburgh, 9a Edinburgh Bio Quarter, 9 Little France Road, Edinburgh EH16 4UX, UK. ²Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. ³Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, UK. ⁴Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK. ⁵Centre for Dementia Studies, Brighton and Sussex Medical School, Brighton, UK. ⁶Old Age Faculty, Royal College of Psychiatrists, London, UK. ⁷Alzheimer's Society, London, UK. ⁸Dementia Research Centre, Department of Neurodegenerative Disease, UCL, London, UK. ⁹Faculty of Medicine, University of Southampton, Southampton, UK. ¹⁰St George's University Hospitals NHS Foundation Trust, London, UK. ¹¹Division of Neuroscience & Experimental Psychology, University of Manchester, Manchester, UK. ¹²Department of Psychiatry, University of Oxford, Oxford, UK. ¹³Alzheimer's Research UK, Cambridge, UK. ¹⁴Department of Psychiatry, University of Cambridge, Cambridge, UK. ¹⁵Alzheimer Scotland, Edinburgh, UK. ¹⁶Imperial College Healthcare NHS Trust, London, UK. ¹⁷East and North Hertfordshire NHS Trust, Stevenage, UK. ¹⁸Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.

* Correspondence: craig.ritchie@ed.ac.uk

†Craig W. Ritchie, Tom C. Russ, Martin N. Rossor and Alistair Burns contributed equally to this work.

¹Centre for Dementia Prevention, University of Edinburgh, 9a Edinburgh Bio Quarter, 9 Little France Road, Edinburgh EH16 4UX, UK

²Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

Full list of author information is available at the end of the article



Received: 4 April 2018 Accepted: 6 April 2018

Published online: 30 July 2018

Reference

1. Ritchie C, et al. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. *Alzheimer's Research & Therapy*. 2017;9:85. <https://doi.org/10.1186/s13195-017-0312-4>.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

